Aerie Pharmaceuticals, Inc.
Simbolis: AERI
NASDAQ
15.25
USDRinkos kaina šiandien
-9.4457
P/E santykis
0.2147
PEG koeficientas
753.62M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
Aerie Pharmaceuticals, Inc. (AERI) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 691.88 | 139.8 | 240.4 | 309.2 | |||||||||||
balance-sheet.row.short-term-investments | 504.72 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.net-receivables | 364.41 | 158.8 | 56 | 38.4 | |||||||||||
balance-sheet.row.inventory | 174.37 | 40.4 | 27.1 | 21.1 | |||||||||||
balance-sheet.row.other-current-assets | 56.18 | 16.6 | 8.3 | 7.7 | |||||||||||
balance-sheet.row.total-current-assets | 1286.84 | 355.6 | 331.8 | 376.3 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 290.73 | 74.1 | 68.3 | 58.1 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 3.98 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 6.32 | 1.6 | 1.9 | 18.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 301.03 | 75.7 | 70.3 | 76.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.account-payables | 34.5 | 8.3 | 8.8 | 12.8 | |||||||||||
balance-sheet.row.short-term-debt | 18.45 | 4.4 | 4.9 | 5.5 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 1253.65 | 256.3 | 210.4 | 188.7 | |||||||||||
Deferred Revenue Non Current | 275.63 | 64.3 | 50.9 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 164.69 | 48 | 39.9 | 65.4 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 1542.75 | 323.7 | 273.6 | 202 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 101.17 | 26.1 | 15.1 | 17.6 | |||||||||||
balance-sheet.row.total-liab | 2036.03 | 448.7 | 378.1 | 285.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.19 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -4645 | -1153.9 | -1079.1 | -896 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -2.15 | -0.1 | -0.1 | -0.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 4198.8 | 1136.7 | 1103.1 | 1063 | |||||||||||
balance-sheet.row.total-stockholders-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 1587.87 | 431.4 | 402 | 452.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | -448.16 | -17.3 | 24 | 166.9 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 1587.87 | - | - | - | |||||||||||
Total Investments | 508.71 | 102.6 | 88.8 | 165.3 | |||||||||||
balance-sheet.row.total-debt | 1272.1 | 260.6 | 215.3 | 194.2 | |||||||||||
balance-sheet.row.net-debt | 1084.93 | 223.5 | 63.7 | 50.2 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 | |||||||||||
cash-flows.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 18.4 | 29.5 | 40.1 | 45.1 | |||||||||||
cash-flows.row.change-in-working-capital | 5.69 | -92.6 | 44.9 | -24 | |||||||||||
cash-flows.row.account-receivables | -9.31 | -12.8 | -17.7 | -35.6 | |||||||||||
cash-flows.row.inventory | -15.16 | -12.1 | -5.2 | -10.3 | |||||||||||
cash-flows.row.account-payables | -7.51 | 21.6 | 16.9 | -270.8 | |||||||||||
cash-flows.row.other-working-capital | 37.68 | -89.2 | 50.9 | 292.7 | |||||||||||
cash-flows.row.other-non-cash-items | -0.53 | 1.2 | -0.7 | 9.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 7.17 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -165.66 | -132.4 | -116.6 | -165.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 151.88 | 117.5 | 192.9 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -7.8 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -18.3 | -18.2 | 73.2 | -183.2 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -8.3 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 2.42 | 3 | -0.9 | 0.7 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.96 | 0 | 8.3 | 274.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.38 | 3 | -0.9 | 274.8 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -7.75 | -114.4 | 7.6 | -58.9 | |||||||||||
cash-flows.row.cash-at-end-of-period | 187.16 | 37.2 | 151.6 | 143.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 194.92 | 151.6 | 143.9 | 202.8 | |||||||||||
cash-flows.row.operating-cash-flow | 7.17 | -99.2 | -64.7 | -150.4 | |||||||||||
cash-flows.row.capital-expenditure | -4.53 | -3.3 | -3.1 | -10 | |||||||||||
cash-flows.row.free-cash-flow | 2.64 | -102.4 | -67.8 | -160.4 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 213.94 | 194.1 | 83.1 | 69.9 | |||||||||||
income-statement-row.row.cost-of-revenue | 23.52 | 26.8 | 25.3 | 4.8 | |||||||||||
income-statement-row.row.gross-profit | 190.42 | 167.3 | 57.8 | 65.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 87.57 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.operating-expenses | 217.13 | 213.6 | 213.5 | 252.5 | |||||||||||
income-statement-row.row.cost-and-expenses | 240.65 | 240.5 | 238.8 | 257.4 | |||||||||||
income-statement-row.row.interest-income | 0.88 | 0.1 | 2 | 3 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 2.3 | 22.8 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.99 | -28.9 | -22.2 | -12.2 | |||||||||||
income-statement-row.row.interest-expense | 11.99 | 28.9 | 26.5 | 15.3 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 20.17 | 37.5 | 34.2 | 18.1 | |||||||||||
income-statement-row.row.ebitda-caps | -3.07 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -23.24 | -45.3 | -155.7 | -187.5 | |||||||||||
income-statement-row.row.income-before-tax | -35.23 | -74.2 | -177.9 | -199.7 | |||||||||||
income-statement-row.row.income-tax-expense | 1.32 | 0.6 | 5.2 | -0.1 | |||||||||||
income-statement-row.row.net-income | -36.55 | -74.8 | -183.1 | -199.6 |
Dažnai užduodami klausimai
Kas yra Aerie Pharmaceuticals, Inc. (AERI) bendras turtas?
Aerie Pharmaceuticals, Inc. (AERI) bendras turtas yra 431391000.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra 69440000.000.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.862.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -2.211.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra -0.385.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra -0.233.
Kas yra Aerie Pharmaceuticals, Inc. (AERI) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -74810000.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 260643000.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 213642000.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 54093000.000.